Adverum Biotechnologies Inc expected to post a loss of $1.81 a share - Earnings Preview

Adverum Biotechnologies

14/05/2025 12:01

Adverum Biotechnologies Inc ADVM.OQ ADVM.O is expected to show no change in quarterly revenue when it reports  results on May 16 (estimated) for the period ending March 31 2025

‚ÄčLSEG's mean analyst estimate for Adverum Biotechnologies Inc is for a loss of $1.81 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Adverum Biotechnologies Inc is $24.00‚Äč, above‚Äč its last closing price of $2.22. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.36
-1.96
Missed
-44.2
Sep. 30 2024
-1.29
-1.31
-1.30
Beat
0.5
Jun. 30 2024
-1.44
-1.47
-0.89
Beat
39.4‚Äč
Mar. 31 2024
-1.55
-1.40
-1.50
Missed
-6.8
‚Äč‚ÄčDec. 31 2023
-3.35
-3.37
-2.30
Beat
31.7
Sep. 30 2023
-3.06
-3.15
-3.30
Missed
-4.7‚Äč
Jun. 30 2023
-3.12
-3.29
-3.10
Beat
5.7
Mar. 31 2023
-3.20
-3.20
-2.90
Beat
9.5

This summary was machine generated May 14 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)